Dr. Hans Lee on the phase 1/2 trial of MRNA-2808 in relapsed or refractory myeloma
Hans Lee, MD, director of Myeloma Research at the Sarah Cannon Research Institute, discusses an early phase 1/2 clinical trial evaluating the investigational therapy mRNA-2808 in heavily pretreated patients with relapsed or refractory myeloma at the 2026 ASCO Annual Meeting.
▶︎
Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma
▶︎
John Mascarenhas, MD, discusses the phase 3 SENTRY trial
▶︎
Drs. Ghobrial and Nadeem discuss the phase 2 CAR-PRISM trial
▶︎
Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL
▶︎
Sacha 'Borat' Baron Cohen Asks Melanie "What Her Price Is" | Friday Night With Jonathan Ross
▶︎
Princess Of Boogie Woogie Delights Everyone
▶︎
"This Food Can Repair DNA & Starve Cancer!" - What You NEED TO KNOW!
▶︎
Watch Ukrainian Drones OBLITERATE a Russian Jet
▶︎
How US Air Force B 52 Pilot Performed an Emergency Takeoff at Full Speed
▶︎
Understanding Multiple Myeloma (Multiple Myeloma Explained Clearly)
▶︎
The French Do Not Care About Work
▶︎
How can clinicians deliver best-in-class care?
▶︎
Wenn der Tod ein Anfang ist | Die Nordreportage | NDR
▶︎
Dr. Nirav Shah on the next iteration in CAR-T cell therapy in blood cancer
▶︎
Your immune system will kill cancer itself—WITHOUT chemotherapy or surgery: just ONE secret. Spon...
▶︎
I Built Retracting Casters that are Actually GOOD
▶︎
How does the immune landscape predict therapy in response in AML, MDS
▶︎
Andrew Waters, PhD, on KRAS Breakthroughs and Future Treatments - Project Purple Podcast Episode 330
▶︎
What Ukraine’s Drone-on-Drone Warfare Is Really Like | Crossfire | Daily Mail
▶︎